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Changes in prescribing patterns of antiepileptic drugs (AEDs) in pregnant women with epi-
lepsy would be expected to affect the risk of major congenital malformations (MCMs). To test
this hypothesis, we analyzed data from an international pregnancy registry (EURAP).
Methods
EURAP is an observational prospective cohort study designed to determine the risk of MCMs
after prenatal exposure to AEDs. The Cochrane-Armitage linear trend analysis was used to
assess changes in AED treatment, prevalence of MCMs, and occurrence of generalized tonic-
clonic seizures (GTCs) over 3 time periods: 2000–2005 (n = 4,760), 2006–2009 (n = 3,599),
and 2010–2013 (n = 2,949).
Results
There were pronounced changes in the use of specific AEDs over time, with a decrease in the
use of valproic acid and carbamazepine and an increase in the use of lamotrigine and levetir-
acetam. The prevalence of MCMs with monotherapy exposure decreased from 6.0% in
2000–2005 to 4.4% in 2010–2013. The change over time in MCM frequency after mono-
therapy exposure showed a significant linear trend in the crude analysis (p = 0.0087), which was
no longer present after adjustment for changes in AED treatment (p = 0.9923). There was no
indication of an increase over time in occurrence of GTCs during pregnancy.
Conclusions
There have been major changes in AED prescription patterns over the years covered by the
study. In parallel, we observed a significant 27% decrease in the prevalence of MCMs. The
results of adjusting the trend analysis for MCMs for changes in AED treatment suggest that
changes in prescription patterns played a major role in the reduction of teratogenic events.
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Since the first report of an association between fetal ex-
posure to antiepileptic drugs (AEDs) and an increased risk
of major congenital malformations (MCMs),1 there have
been major advances in characterizing the teratogenicity of
individual AEDs. During the last decade, data from large
prospective AEDs and pregnancy registries2–7 and other
prospective observational cohort studies8–10 have enabled
comparisons of risks associated with different
treatments.2–7 These data have consistently shown that, in
comparison with many other AEDs, valproic acid is asso-
ciated with a higher prevalence of MCMs as well as an
increased risk for impaired cognitive and behavioral de-
velopment of the exposed offspring.2–11 The risks associ-
ated with valproic acid appear to be dose-dependent.2–10,12
These findings provided physicians with tools for more
rational, evidence-based treatment decisions and prompted
the US Food and Drug Administration13 and the European
Medicines Agency (EMA)14 to tighten the restrictions on
the use of valproic acid in women of childbearing potential.
Recent reports indicate that prescription patterns for
women with epilepsy have changed over time and that the
use of valproic acid has been declining in women15,16 in-
cluding women during pregnancy.17–19 However, in-
formation on possible changes in pregnancy outcomes in
parallel with changes in AED utilization are scarce.17,19,20
In this study, we used data from the EURAP registry’s lon-
gitudinal prospective cohort to analyze changes in AED
treatment and pregnancy outcomes over the 14-year period
(2000–2013) preceding EMA’s introduction of further
restrictions on valproic acid use.
Methods
Eligibility criteria and study procedures
The current analysis assessed time trends in the use of
different AED treatments and in teratogenic outcomes
based on data from the EURAP international registry,
whose primary aim is to compare the risk of MCMs at 1
year after birth in offspring exposed to AED treatments
prenatally. The EURAPmethodology has been described in
detail before.6
Eligible for prospective assessment in EURAP are preg-
nancies exposed to AEDs at conception, enrolled within
gestation week 16 (based on the date of the last menstrual
period) and before fetal outcome is known. Information
on demographics, type of epilepsy, seizure frequency,
comorbidities, family history of MCMs, drug treatment,
and other risk factors is obtained in early pregnancy.
Follow-up data are obtained after each trimester, at birth,
and 1 year after birth. Data are collected by the treating
physician and transferred online to a national coordinator,
who reviews the reports for completeness and accuracy
before transmission to the central database in Milan, Italy.
The registry was established in 1999 and has involved 42
countries with >1,500 collaborators (coinvestigators, links.lww.
com/WNL/A946). The prevalence of MCMs associated with
the 8 most common monotherapies at different dose levels has
recently been reported.6 In the current analysis, we focus on
changes in use of different AED treatments and in teratogenic
outcomes for pregnancies where conception (based on date of
last menstrual period) occurred between 2000 and 2013. Due
to the need for follow-up of outcomes and data validation, the
cutoff date for the present analysis was set at May 20, 2016, at
which point 21,875 pregnancies had been registered.
Exclusions
We excluded from the current analysis retrospectively
ascertained pregnancies, those occurring in women without
epilepsy, those for which physicians failed to submit reports
within preset deadlines, and those for which follow-up was
not yet completed at the current census. We also excluded
pregnancies where AEDs were switched or withdrawn dur-
ing the first trimester, those exposed to other potentially
teratogenic drugs, and those with comorbidities associated
with teratogenic risks. For the analysis of teratogenic out-
comes, we also excluded intrauterine deaths and abortions
induced for causes other than fetal abnormalities and preg-
nancies in which fetal outcome could not be determined;
pregnancies that resulted in offspring with genetic or chro-
mosomal abnormalities were also excluded, as well as those
with incomplete 12 months’ postnatal follow-up. The se-
lection process is summarized in figure 1.
Definition of drug exposures
Pregnancies were classified based on type and dosage of
AEDs at conception. Seizures were classified as either
generalized tonic-clonic (GTC) or other types, and epi-
lepsy syndromes broadly according to International League
Against Epilepsy criteria at the time EURAP was
launched.21 In the EURAP protocol, the term “GTC seiz-
ures” includes GTC as well as focal to bilateral tonic-clonic
seizures. Family history of MCMs refers to the proband’s
parents, excluding cerebral malformations causally associ-
ated with the maternal epilepsy. Folate supplementation
was arbitrarily deemed appropriate if initiated at least 3
months before conception and maintained throughout the
first trimester irrespective of dose, provided that it was no
less than 0.4 mg/d.
Glossary
AED = antiepileptic drug; EMA = European Medicines Agency; GTC = generalized tonic-clonic; MCM = major congenital
malformation.
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Outcomes
Reporting physicians were instructed to report descriptively
anything that they considered to be a potential abnormality in
the offspring. These reports were reviewed and classified by an
outcome committee unaware of the type of exposure. MCMs
were defined as structural abnormalities with surgical, medi-
cal, functional, or cosmetic importance, and classified
according to EUROCAT criteria 2005.22 To calculate fre-
quencies of MCMs, the numerator was the sum of all live
births plus pregnancy losses with confirmedMCMs, while the
Figure 1 Study population and selection process
AED = antiepileptic drug.
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denominator included live births, pregnancies terminated
electively for MCMs, and perinatal deaths.
Information on obstetric outcomes and occurrence of GTC
seizures was also obtained from reporting physicians.
Statistical analysis
To analyze time trends, pregnancies were divided into 3
groups based on the year of conception: 2000–2005,
2006–2009, and 2010–2013. The time periods were defined
before the analysis to reflect hypothesized differences in
treatment selection as a result of emerging data on the com-
parative teratogenicity of AEDs, taking also into account the
need to ensure reasonable numbers of pregnancies in all 3
periods. The first period, 2000 through 2005, was selected as
reference because several important studies demonstrating
increased risks with valproic acid were published in
2004–2005.23–25 Further influential studies providing com-
parative data on teratogenic effects of different AEDs were
published between 2009 and 2011,5,9,26 justifying a split be-
tween 2006–2009 and 2010–2013 in our analysis.
The Cochrane-Armitage test, available in procedure MULT-
TEST of SAS software version 9.4, was used for linear trend
analysis of the frequency of MCMs during the 3 time periods.
This analysis was confined to pregnancies with exposure to the 8
most frequently used AEDs (in total 97.4% of all monotherapy
exposures) for which the frequency of MCMs at different dose
levels has been defined in a previous publication.6 As a second
step, and to assess the effect of changes in AED treatment on the
Table 1 Demographics and clinical details of the study cohort (n = 11,308)
2000–2005 (n = 4,760),
mean (range)
2006–2009 (n = 3,599),
mean (range)
2010–2013 (n = 2,949),
mean (range)
Maternal age at conception, y 29.4 (14.1–46.4) 29.9 (14.2–46.6) 30.4 (15.4–46.2)
Duration of pregnancy at enrolment,
wk
8.8 (0–16) 8.1 (1–16) 8.2 (1–16)
2000–2005 (n = 4,760),
n (%)
2006–2009 (n = 3,599),
n (%)
2010–2013 (n = 2,949),
n (%)
Parental history of major congenital malformations
Negative 4,665 (98.5) 3,552 (98.9) 2,895 (99.0)
Positive 69 (1.5) 38 (1.1) 30 (1.0)
Parity
0 2,864 (60.2) 2,160 (60.0) 1,734 (58.8)
1 1,484 (31.2) 1,139 (31.7) 990 (33.6)
2 312 (6.5) 240 (6.7) 189 (6.4)
3 or higher 100 (2.1) 58 (1.6) 36 (1.2)
Type of epilepsy
Idiopathic generalized 1,733 (36.4) 1,327 (36.9) 1,168 (39.6)
Localization-related 2,353 (49.4) 1,919 (53.3) 1,600 (54.3)
Undetermined/unclassifiable 674 (14.2) 353 (9.8) 181 (6.1)
Folic acid intakea
Appropriate 1,565 (32.9) 1,323 (36.8) 1,227 (41.6)
Inappropriate 3,135 (65.9) 2,222 (61.7) 1,700 (57.6)
Missing information 60 (1.2) 54 (1.5) 22 (0.8)
Ultrasonography (n = 10,381 cases, including deliveries,
perinatal deaths, and induced abortions for fetal
anomalies)
n = 4,319 (%) n = 3,273 (%) n = 2,690 (%)
Not performed 328 (7.6) 245 (7.5) 157 (5.8)
Performed 3,991 (92.4) 3,028 (92.5) 2,533 (94.2)
a Folate supplementation was arbitrarily deemed appropriate if started at least 3months before conception andmaintained throughout the first trimester of
pregnancy at a dose of no less than 0.4 mg/d.
e4 Neurology | Volume 93, Number 9 | August 27, 2019 Neurology.org/N
Copyright © 2019 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
prevalence of MCMs, the linear trend analysis of the fre-
quency of MCMs was adjusted for changes in AED treat-
ment including type of AED and dose categories6 by
resorting to the stratified version of Cochrane-Armitage
test. The same statistical approach was also used to analyze
time trends in proportion of pregnancies associated with
GTC seizures, which was a secondary outcome in the
present analysis.
Data availability
Data not shown in this article will be shared by request from
any qualified investigator.
Standard protocol approvals, registrations,
and patient consents
The protocol was approved by ethics committees of partici-
pating centers and informed consent was obtained from all
women, in writing or orally depending on the requirements in
the different countries.
Results
Of the 21,875 pregnancies in the database, 11,308 prospective
pregnancies (9,724 from Europe, 1,425 from Asia-Oceania,







Proportion of pregnancies exposed to monotherapy vs polytherapy during
the first trimester
n = 4,760 n = 3,599 n = 2,949
Monotherapy 3,825 (80.4) 2,934 (81.5) 2,407 (81.6)
Polytherapy 935 (19.6) 665 (18.5) 542 (18.4)
Monotherapy exposures during first trimester of pregnancy (n = 9,166) n = 3,825 n = 2,934 n = 2,407
Lamotrigine 994 (26.0) 1,086 (37.0) 1,006 (41.8)
Carbamazepine 1,259 (32.9) 655 (22.3) 419 (17.4)
Valproic acid 891 (23.3) 541 (18.4) 276 (11.5)
Levetiracetam 53 (1.4) 220 (7.5) 406 (16.9)
Oxcarbazepine 146 (3.8) 151 (5.1) 115 (4.8)
Phenobarbital 207 (5.4) 84 (2.9) 64 (2.7)
Topiramate 49 (1.3) 93 (3.2) 59 (2.4)
Phenytoin 97 (2.5) 37 (1.3) 14 (0.6)
Other monotherapies 129 (3.4) 67 (2.3) 48 (2.0)
Polytherapy during first trimester (n = 2,142) n = 935 n = 665 n = 542
First trimester polytherapy with valproic acid 335 (35.8) 184 (27.7) 119 (22.0)
First trimester polytherapy without valproic acid 600 (64.2) 481 (72.3) 423 (78.0)
Mean dose of valproic acid in monotherapy exposures, mg/d (n = 1,708) n = 891 n = 541 n = 276
829.8 802.5 777.9
Mean dose of valproic acid in polytherapy exposures, mg/d (n = 638) n = 335 n = 184 n = 119
946.8 1,011.1 877.7
Mean dose of carbamazepine in monotherapy exposures, mg/d (n = 2,333) n = 1,259 n = 655 n = 419
655.6 637.7 650.9
Fivemost commonpolytherapies, first trimester of pregnancy (n = 743 cases) n = 299 n = 236 n = 208
Lamotrigine + valproic acid 117 (39.1) 70 (29.6) 46 (22.1)
Lamotrigine + levetiracetam 32 (10.7) 75 (31.8) 85 (40.9)
Carbamazepine + levetiracetam 29 (9.7) 50 (21.2) 48 (23.1)
Carbamazepine + lamotrigine 73 (24.4) 25 (10.6) 15 (7.2)
Carbamazepine + valproic acid 48 (16.1) 16 (6.8) 14 (6.7)
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and 159 from the Americas) were enrolled over the pre-
defined time periods (table 1 for demographic and clinical
data). Of these, 10,291 occurring in a total of 8,958 women
(1,032 contributed two pregnancies, 73 three pregnancies,
and 1 four or more pregnancies) met the criteria for inclusion
in the analysis of treatment changes and seizure control,
whereas 9,023 occurring in a total of 7,839 women (923
contributed two pregnancies, 63 three pregnancies, and 1 four
or more pregnancies) met the criteria for analysis of terato-
genic outcomes (figure 1). Maternal age, duration of preg-
nancy at enrollment, parental history of MCMs, parities, types
of epilepsy, and use of prenatal ultrasound investigation were
similar across the 3 time periods.
The proportion of pregnancies with appropriate folic acid
supplementation increased over time, although it remained
below 50% throughout the study period. The proportion of
pregnancies exposed to AED monotherapy was similar across
all periods (80.4%–81.6%), but there were major changes
over time in the type of AEDs used in monotherapy (table 2).
In particular, there was a progressive decline in the use of
valproic acid and carbamazepine, and an increase in the use of
lamotrigine and levetiracetam (figure 2). The use of valproic
acid in combination therapy also decreased markedly from the
first to the second and to the third time periods (table 2).
Teratogenic outcomes and seizure control data during the 3 time
periods are summarized in table 3. The prevalence of MCMs
after monotherapy exposure decreased from 6.0% during
2000–2005 to 4.4% during 2010–2013. Corresponding figures
for polytherapy exposure were 8.3% and 6.1%, respectively. The
change over time in frequency of MCMs after monotherapy
exposure showed a significant negative linear trend in the crude
analysis (p = 0.0087), which was no longer present after ad-
justment for changes in AED treatment (p = 0.9923).
Figure 3 shows data for 8 broad categories of MCMs detected
over the 3 time periods after monotherapy and polytherapy
exposure. Compared with the first time period, the prevalence
of MCMs decreased for most categories except for renal
malformations and for multiple MCMs.
There were no significant changes over time in the proportion
of pregnancies associated with GTC seizures (p = 0.1210)
(table 3).
Discussion
The present study demonstrates a significant trend for the
prevalence of MCMs to decrease during the 14-year period
that preceded the strengthening of EMA restrictions on the
use of valproic acid. After adjustment for changes in AED
treatment, this trend was no longer present, suggesting that
the improved teratogenic outcomes were causally related to
the changes in type of AED exposure. During the study pe-
riod, the use of valproic acid monotherapy decreased mark-
edly from 25.9% of all monotherapies in 2000 to 6.7% in 2013,
and that of carbamazepine from 41.1% to 13.5% (figure 2).
The use of valproic acid in polytherapy regimens also declined
markedly during the same period, whereas the use of lamo-
trigine and levetiracetam increased considerably (table 2).
Since valproic acid is associated with a much higher risk for
Figure 2 Proportion of monotherapies per year
Proportion of different antiepileptic drug monotherapies (expressed as % of all monotherapy exposures) over time in pregnancies enrolled in EURAP from
2000 through 2013.
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MCMs than lamotrigine and levetiracetam,2,3,6,27 it is rea-
sonable to assume that the decrease in occurrence ofMCMs is
explained mainly by the pronounced decline in exposure to
valproic acid. This assumption is further supported by the fact
that the prevalence of types of MCMs found to be associated
with valproic acid exposure in previous studies, such as hy-
pospadias, neural tube defects, and polydactyly,6,28–31 also
decreased over time (figure 3). Other changes in type of AED
may also have contributed to the improved teratogenic out-
comes. In particular, carbamazepine and phenobarbital, the
use of which declined during the study period, have been
associated with higher risks of MCMs compared with leve-
tiracetam and lamotrigine.2,3,6,27
The risk of MCMs with several AEDs, including valproic acid
and carbamazepine, has been shown to be dose-dependent.2,3,6,7
However, changes over time in the doses of valproic acid and
carbamazepine (table 2) were not of amagnitude that is likely to
explain the improved teratogenic outcomes. In addition, there
were no major changes over time in the prevalence of MCMs
with the 3 most frequently used AEDs—lamotrigine, carba-
mazepine, or valproic acid (data not shown)—supporting the
interpretation that the decrease in overall prevalence of MCMs
is a result of changes in drug selection rather than a time effect.
Although there was an increase over time in the use of appro-
priate folate supplementation (table 1), a recent analysis of data
from the EURAP cohort did not identify a protective effect of
folate against the risk ofMCMs associatedwith AEDexposure.6
Therefore, it is unlikely that greater use of folic acid had a major
role in the reduction in teratogenic outcomes shown by the
current analysis.
A challenge in managing epilepsy during pregnancy is to
balance the teratogenic risks of treatment against the fetal and
maternal risks associated with poorly controlled seizures.30,32
It is therefore reassuring that there was no indication of de-
terioration in control of GTC seizures or in the occurrence of
status epilepticus over time in parallel with changes in pre-
scribing patterns, and, in particular, with the increased use of
lamotrigine and levetiracetam at the expense of valproic acid
and carbamazepine (table 3). This is somewhat surprising
because earlier EURAP findings had suggested poorer control
of GTC seizures during pregnancy with lamotrigine com-
pared with valproic acid use.33 Possibly, unchanged seizure








Obstetric outcome (n = 11,308 all cases) n = 4,760 n = 3,599 n = 2,949
Delivered 4,284 (90.0) 3,270 (90.9) 2,682 (91.0)
Induced abortions, intrauterine deaths, and perinatal deaths 476 (10.0) 329 (9.1) 267 (9.0)
Generalized tonic-clonic seizures during pregnancy (n = 10,291 deliveries) n = 4,272 n = 3,254 n = 2,675
Yes 833 (19.5) 636 (19.5) 460 (17.2)
No (either seizure-free or other seizure types) 3,439 (80.5) 2,618 (80.5) 2,215 (82.8)
Status epilepticus during pregnancy (n = 10,291 deliveries) n = 4,275 n = 3,250 n = 2,677
Convulsive status epilepticus 18 (0.4) 9 (0.3) 6 (0.2)
Nonconvulsive status epilepticus 20 (0.5) 11 (0.3) 3 (0.1)
No status epilepticus 4,237 (99.1) 3,230 (99.4) 2,668 (99.7)
Teratogenic outcomes, monotherapy (n = 7,162; 8 most common AEDs) n = 2,984 n = 2,246 n = 1,932
Major congenital malformations 180 (6.0) 108 (4.8) 85 (4.4)
No major congenital malformations 2,804 (94.0) 2,138 (95.2) 1,847 (95.6)
Teratogenic outcomes, all monotherapy cases (n = 7,350) n = 3,087 n = 2,294 n = 1,969
Major congenital malformations 181 (5.9) 109 (4.8) 86 (4.4)
No major congenital malformations 2,906 (94.1) 2,185 (95.2) 1,883 (95.6)
Teratogenic outcomes, polytherapy (n = 1,673) n = 736 n = 508 n = 429
Major congenital malformations 61 (8.3) 35 (6.9) 26 (6.1)
No major congenital malformations 675 (91.7) 473 (93.1) 403 (93.9)
Abbreviation: AED = antiepileptic drug.
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outcomes despite greater use of lamotrigine could be
explained by increased awareness of the need for serum drug
level monitoring and dose adjustments during pregnancy34
and also by more careful individualization of AED selection
where valproic acid may have been reserved for the more
difficult to treat. It should be acknowledged that there are
individual cases in whom valproic acid is the most and
sometimes the only effective treatment, particularly in gen-
eralized epilepsies.32
Other authors have reported changes in AED utilization over
time in young women15,16 or during pregnancy,18 generally
showing a decrease in the use of valproic acid. The Australian
Register of AEDs in Pregnancy, which contributes pregnancies
to EURAP (5.5% of the current cohort), compared data on 855
pregnancies enrolled in 1995–2005 with 801 pregnancies en-
rolled in 2006–2012 and found a significant decrease in the use
of carbamazepine and valproic acid, albeit smaller than in our
cohort, but no decrease in frequency of MCMs.19 A more
recent report from the United Kingdom and Ireland pregnancy
register also found a decrease in the use of valproic acid and
carbamazepine and an increase in the use of lamotrigine and
levetiracetam between 1996 and 2016, which was associated
with a small, not significant annual reduction in MCM rate.17
Our study has a number of limitations. First, the EURAP co-
hort is not population-based and most of the enrolled patients
are managed by physicians with a special interest in the man-
agement of epilepsy in women of childbearing potential.
Therefore, the observed trends in prescribing patterns may not
be representative of trends in women with epilepsy at large.
However, this does not invalidate the important observation
that the reported treatment changes were associated with a re-
duced frequency of MCMs. Our analysis covers 14 years of
enrolment, from 2000 to 2013. Hence, it does not assess the
effect of EMA’s tightened restrictions on the use of valproic acid
in 2014 (EMA), but it rather reflects adjustments in prescribing
patterns based on emerging data on the teratogenic potential of
individual AEDs. In fact, our selection of the 3 time periods took
into account time-dependent advances in level of evidence for
teratogenic risks. Admittedly, a comparison between outcomes
in the 3 time periods is also a comparison of different pop-
ulations. However, apart from differences in AED treatment,
demographic and clinical data were very similar across the
treatment periods, supporting the interpretation that the ob-
served differences in teratogenic outcomes are at least in part the
result of changes in treatment patterns.
Data from this large international prospective registry docu-
mented major changes in treatment patterns in women with
epilepsy during pregnancy over a 14-year period, with de-
creased use of valproic acid and carbamazepine and increased
use of lamotrigine and levetiracetam. These changes were as-
sociated with a reduction by approximately 27% in the preva-
lence of MCMs, without any indication of deterioration in
overall control of GTC seizures. Considering the number of
women with epilepsy worldwide who become pregnant while
on treatment, this improvement in outcome has major public
health implications. Given that the current analysis was limited
to the 8 most frequently used AEDs and MCMs as primary
outcome, additional research including continued activity of
the existing pregnancy registries is needed to assess the full
spectrum of potential adverse outcomes, including cognitive
and behavioral outcomes, after prenatal exposure to AEDs.
Figure 3 Prevalence of specific malformations by time period
Prevalence of different categories of major congenital malformations (expressed as % of all exposures) in offspring exposed prenatally to antiepileptic drugs
in monotherapy or polytherapy during the 3 study periods.
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